Science Explorer Back to mapMap

Most cited papers from Istituti Ospitalieri di Cremona

What are the most cited papers from Istituti Ospitalieri di Cremona?

The most cited paper from Istituti Ospitalieri di Cremona is "Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy" (Giacomo Grasselli et al., 2020), with 5,912 citations. Next come "Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial" (2,223) and "70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer" (2,097).

Showing 50 of 60 papers. Every paper with more than 201 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy Giacomo Grasselli et al. · JAMA Open access114 authors 6 Apr 2020 5,912
2 Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial Charles S. Fuchs et al. · The Lancet Open access 2 Oct 2013 2,223
3 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer Fátima Cardoso et al. · New England Journal of Medicine Open access 24 Aug 2016 2,097
4 Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy Giacomo Grasselli et al. · JAMA Internal Medicine Open access149 authors 15 Jul 2020 1,747
5 FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study Chiara Cremolini, Fotios Loupakis, Carlotta Antoniotti et al. · The Lancet Oncology Open access 31 Aug 2015 1,111
6 Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer Fotios Loupakis, Chiara Cremolini, Gianluca Masi et al. · New England Journal of Medicine Open access 22 Oct 2014 1,097
7 Comparison between different D ‐ D imer cutoff values to assess the individual risk of recurrent venous thromboembolism: analysis of results obtained in the DULCIS study Gualtiero Palareti, Cristina Legnani, Benilde Cosmi et al. · International Journal of Laboratory Hematology Open access 12 Sep 2015 910
8 ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients Evelina Tacconelli, Maria Adriana Cataldo, Stephanie J. Dancer et al. · Clinical Microbiology and Infection Open access 12 Dec 2013 887
9 Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data François‐Clément Bidard et al. · The Lancet Oncology 11 Mar 2014 848
10 Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial Matthew D. Galsky et al. · The Lancet Open access May 2020 799
11 Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer Fausto Petrelli, Gianluca Tomasello, Karen Borgonovo et al. · JAMA Oncology 27 Oct 2016 758
12 Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia Carlo Salvarani et al. · JAMA Internal Medicine Open access 20 Oct 2020 733
13 Acute pulmonary embolism and COVID-19 pneumonia: a random association? Gian Battista Danzi, Marco Loffi, Gianluca Galeazzi et al. · European Heart Journal Open access 25 Mar 2020 669
14 Out-of-Hospital Cardiac Arrest during the Covid-19 Outbreak in Italy Enrico Baldi, Giuseppe Maria Sechi, Claudio Mare et al. · New England Journal of Medicine Open access 29 Apr 2020 668
15 Cigarette Smoking, Body Mass Index, and Stressful Life Events as Risk Factors for Psoriasis: Results from an Italian Case–Control Study Luigi Naldi et al. · Journal of Investigative Dermatology Open access 27 Jun 2005 645
16 Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome Vittorio Pengo, Amelia Ruffatti, Cristina Legnani et al. · Journal of Thrombosis and Haemostasis Open access 30 Oct 2009 632
17 d -Dimer Testing to Determine the Duration of Anticoagulation Therapy Gualtiero Palareti, Benilde Cosmi, Cristina Legnani et al. · New England Journal of Medicine 25 Oct 2006 629
18 COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study Marina Chiara Garassino et al. · The Lancet Oncology Open access 12 Jun 2020 624
19 The impact of frailty on ICU and 30-day mortality and the level of care in very elderly patients (≥ 80 years) on behalf of the VIP1 study group et al. · Intensive Care Medicine Open access 21 Sep 2017 618
20 MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside Margherita Ratti, Andrea Lampis, Michele Ghidini et al. · Targeted Oncology Open access 25 May 2020 611
21 Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study Giancarlo Agnelli, Gualberto Gussoni, Carlo Bianchini et al. · The Lancet Oncology Sep 2009 601
22 A randomized clinical trial of high‐intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) Guido Finazzi, Roberto Marchioli, Vincenzo Brancaccio et al. · Journal of Thrombosis and Haemostasis Open access 29 Apr 2005 590
23 Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study Francesco Passamonti et al. · The Lancet Haematology Open access 13 Aug 2020 555
24 Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial Kohei Shitara et al. · The Lancet Oncology 21 Oct 2018 532
25 Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study Vittorio Pengo, Amelia Ruffatti, Cristina Legnani et al. · Blood Open access 16 Jul 2011 465
26 Broad targeting of angiogenesis for cancer prevention and therapy Zongwei Wang et al. · Seminars in Cancer Biology Open access 16 Jan 2015 462
27 Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis Enrico Ammirati et al. · Circulation Open access 15 May 2018 449
28 Vitamin D levels and patient outcome in chronic kidney disease Pietro Ravani, Fabio Malberti, Giovanni Luigi Tripepi et al. · Kidney International Open access 8 Oct 2008 438
29 ST-Elevation Myocardial Infarction in Patients With COVID-19 Giulio Giuseppe Stefanini et al. · Circulation Open access 30 Apr 2020 432
30 East–West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort Johan M. Burisch et al. · Gut Open access 20 Apr 2013 432
31 Total Neoadjuvant Therapy in Rectal Cancer Fausto Petrelli, Francesca Trevisan, Mary Cabiddu et al. · Annals of Surgery 18 Jul 2019 415
32 Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients Antonio Curti, Loredana Ruggeri, Alessandra D’Addio et al. · Blood Open access 27 Jul 2011 405
33 The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials Giovanni Fucà et al. · British Journal of Cancer Open access 18 May 2020 397
34 Asymmetrical Dimethylarginine Predicts Progression to Dialysis and Death in Patients with Chronic Kidney Disease Pietro Ravani, Giovanni Luigi Tripepi, Fabio Malberti et al. · Journal of the American Society of Nephrology 8 Jun 2005 379
35 Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study Valentina Guarneri et al. · Journal of Clinical Oncology Open access 10 Apr 2012 368
36 Vascular Involvement in Diabetic Subjects with Ischemic Foot Ulcer: A New Morphologic Categorization of Disease Severity Lanfroi Graziani, Antonio Silvestro, Vittorio Bertone et al. · European Journal of Vascular and Endovascular Surgery Open access 30 Dec 2006 350
37 Prevalence, Metabolic Features, and Prognosis of Metabolically Healthy Obese Italian Individuals Giliola Calori, Guido Lattuada, Lorenzo Piemonti et al. · Diabetes Care Open access 11 Oct 2010 349
38 Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial Chiara Cremolini et al. · The Lancet Oncology Open access 9 Mar 2020 335
39 Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial Miranda Gogishvili et al. · Nature Medicine Open access 25 Aug 2022 318
40 Management and Long-Term Prognosis of Spontaneous Coronary Artery Dissection Corrado Lettieri et al. · The American Journal of Cardiology 10 Apr 2015 310
41 Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis Fausto Petrelli, Diego Signorelli, Michele Ghidini et al. · Cancers ReviewOpen access 27 Feb 2020 304
42 Designing a broad-spectrum integrative approach for cancer prevention and treatment Keith I. Block et al. · Seminars in Cancer Biology Open access180 authors 18 Nov 2015 302
43 The Role of ATF4 Stabilization and Autophagy in Resistance of Breast Cancer Cells Treated with Bortezomib Manuela Milani, Tomasz Rzymski, Howard R. Mellor et al. · Cancer Research 5 May 2009 302
44 Epithelial–mesenchymal transition and breast cancer: Role, molecular mechanisms and clinical impact Chiara Foroni, Massimo Broggini, Daniele Generali et al. · Cancer Treatment Reviews 3 Dec 2011 283
45 Pregnancy in CKD Stages 3 to 5: Fetal and Maternal Outcomes Enrico Imbasciati, Gina Alessandra Gregorini, Gianfranca Cabiddu et al. · American Journal of Kidney Diseases 30 May 2007 282
46 Fatty liver index and mortality: The cremona study in the 15th year of follow-up Giliola Calori, Guido Lattuada, Francesca Ragogna et al. · Hepatology Open access 12 Apr 2011 261
47 Comparison of Microbiological, Histological, and Immunomodulatory Parameters in Response to Treatment with Either Combination Therapy with Prednisone and Metronidazole or Probiotic VSL#3 Strains in Dogs with Idiopathic Inflammatory Bowel Disease Giacomo Rossi, G. Pengo, Marco Caldín et al. · PLoS ONE Open access 10 Apr 2014 257
48 Hypoxia-Inducible Factor-1α Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer Daniele Generali, Alfredo Berruti, Maria Pia Brizzi et al. · Clinical Cancer Research Open access Aug 2006 248
49 COVID-19 kills at home: the close relationship between the epidemic and the increase of out-of-hospital cardiac arrests Enrico Baldi et al. · European Heart Journal Open access 3 Jun 2020 245
50 Management of Patients on Dialysis and With Kidney Transplantation During the SARS-CoV-2 (COVID-19) Pandemic in Brescia, Italy Federico Alberici et al. · Kidney International Reports Open access 4 Apr 2020 242

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.